Brief: Adial Pharmaceuticals Announces Positive In Vivo Data For Purnovate’S PNV-5030 As A Potential Treatment For Chronic Pain
26/09/2022 14:48
Sept 26 (Reuters) - Adial Pharmaceuticals Inc ADIL.O :
* ADIAL PHARMACEUTICALS ANNOUNCES POSITIVE IN VIVO DATA FOR
PURNOVATE’S PNV-5030 AS A POTENTIAL TREATMENT FOR CHRONIC PAIN
* ADIAL PHARMACEUTICALS - PNV-5030 REDUCED PAIN IN AN ANIMAL
MODEL
OF CHRONIC PAIN, AS COMPARED TO BOTH PLACEBO AND ACETAMINOPHEN
Source text for Eikon: ID:nGNXbwlzct
Further company coverage: ADIL.O
((Reuters.Briefs@thomsonreuters.com;;))
Recent news on Adial Pharmaceuticals
See all newsBrief: Adial Pharmaceuticals Announces Name Change To Azora Therapeutics
Brief: Adial Pharmaceuticals Announces Planned Appointment Of Celia Economides As Chief Financial Officer
Brief: Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)
Brief: Adial Pharmaceuticals - Proposed Resale Of Up To 25,148,970 Shares Of Common Stock By Selling Stockholders - SEC Filing
Brief: Adial Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)